Orexo: Zubsolv Rx Data week 8, 2017

Zubsolv tablets showed a market share of 5.50% (5.54%), 4-week rolling average. The total number of Zubsolv tablets sold week 8 (7) reaching 308,626 (321,491). Zubsolv prescriptions (TRx) recorded a market share of 5.53% (5.57%), 4-week rolling average. Total number of prescriptions reaching 11,164 (11,599) during the week. The overall market (buprenorphine/naloxone) show-ed a y/y growth rate of 9.0% (9.4%) (4-week rolling average unit sales). TRx showed a y/y growth rate by 11.3% (11.5%) (4-week rolling average).

Författaren ägde vid analystillfället aktier i bolaget.

Fler bolagsanalyser

Här listas fler bolagsanalyser ifrån Redeyes analysavdelning.

Publicerad Rubrik Analystyp
2017-04-24 Update
2017-04-21 Update
2017-04-21 Update
2017-04-19 Update
2017-04-12 Update
2017-04-11 Update
2017-04-07 Update
2017-04-03 Update
2017-03-31 Update
2017-03-31 Analys
2017-03-30 Analys
2017-03-29 Update
2017-03-28 Update
2017-03-24 Update
2017-03-22 Analys
2017-03-21 Update
2017-03-21 Update
2017-03-17 Update
2017-03-16 Update
2017-03-14 Update
2017-03-14 Update
2017-03-10 Update
2017-03-10 Update
2017-03-07 Update
2017-03-07 Update